Clinical trial
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in…
NCT00121134 · Harold J. Burstein, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00121134 |
|---|---|
| Title | Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer |
| Official title | Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer |
| Lead sponsor | Harold J. Burstein, MD, PhD, Other |
| Collaborators | Genentech, Inc. Industry Beth Israel Deaconess Medical Center Indiana University School of Medicine University of California, San Francisco University of North Carolina |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Cyclophosphamide, Methotrexate, Capecitabine |
| Enrollment | 164 |
| Start date | Jun 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2011 |
| First posted | Jul 21, 2005 |
| Last update posted | Dec 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: